- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
-
Comparing Medicine’s Cost and Effectiveness
-
Pharma Announces $80B Reduction: Who Wins?
-
FDA Calendar Updates: Acusphere, AspenBio, Alkermes
-
20 'Bathwater Babies' and 20 'Dogs with Fleas' Stocks for the Week
-
Galleon's Q408: SPY Pays Off Alongside Reduced Equity Positions
-
Where Might Genentech Investors Redeploy $47B?
-
Corporate Flight from the U.S. - The Next Step?
-
20 'Babies with Bathwater' and 3 'Dogs with Fleas' for the Week
-
Five Autism Stocks
-
Autism in the News - and Stocks that Could Benefit
-
What to Buy and Why: Barron's 2009 Roundtable, Part III
-
Hedge Fund Tracking: Barry Rosenstein's Jana Partners, Q3 2008
-
Tuesday Options Update: VIX, XLF, YHOO, IRM, SHPGY, SKX, NTES, BBBY
-
Shire May Have Another Winner in Purchase of Jerini
-
Tuesday's Options Report: XLF, MS,LEH, GS, EWJ, SRZ, SHPGY, INTU
-
Is Shire Eying Questcor as a Potential Takeover Target?
-
Thursday's Options Report: Shire, Ford, YHOO, FO, XLF, MSFT, EBAY, ESRX
-
Biotech Fund IBB May Ride the M&A Frenzy, but It's Still Wildly Volatile
-
Biotech Day in Review: New River/Shire Win Approval for ADHD Drug
-
Biotech Day In Review: Genentech Loses Cabilly Patent Ruling
-
Biotech Day in Review: Shire Buys New River for $2.6 Billion
-
Shire to Buy New River Pharmaceuticals for $2.6 Billion
-
Barron's 2007 Analyst Roundtable, Part III
-
Biotech Stocks Day-In-Review: Coley Drops After Ending Hepatitis C Program
-
Biotech Stocks Day-in-Review: Lilly Drug Effective In Pancreatic Cancer
-
Bristol-Myers Squibb Partners with AstraZeneca in $1.2 Billion Pact
-
FDA Approvable Letters for New River Pharmaceuticals, Shire, Allergan and Perrigo
-
Analyst Upgrades & Downgrades for Thursday, July 20, 2006